ADMA ADMA Biologics Inc

$17.18

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

ADMA Biologics is poised for a potentially transformative earnings report on November 5, 2025, as the company continues to navigate its growth trajectory with a market cap of over $3.6 billion. Investors are keenly watching to see if ADMA can surpass the EPS estimate of $0.15, especially with the whisper number slightly lower at $0.13, indicating a cautious optimism among analysts. The revenue estimate stands at $130.52 million, reflecting the company's ongoing efforts to expand its market presence and enhance its product offerings. Despite the absence of recent news, ADMA's strategic focus on bolstering its plasma-derived therapeutics portfolio could be a pivotal factor in driving future growth, making this earnings report a critical indicator of the company's ability to capitalize on its market opportunities.

Updated On 11/21/2025

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.

Website: https://www.admabiologics.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1368514
Address
C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY, NJ, US
Valuation
Market Cap
$5.08B
P/E Ratio
26.31
PEG Ratio
0.00
Price to Book
14.57
Performance
EPS
$0.81
Dividend Yield
—
Profit Margin
46.40%
ROE
81.60%
Technicals
50D MA
$18.09
200D MA
$17.41
52W High
$23.64
52W Low
$6.19
Fundamentals
Shares Outstanding
239M
Target Price
$25.74
Beta
0.53

ADMA EPS Estimates vs Actual

● Estimated
● Actual

ADMA News & Sentiment

Nov 21, 2025 • Zacks Commentary NEUTRAL
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Nov 19, 2025 • Zacks Commentary NEUTRAL
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
Nov 18, 2025 • Zacks Commentary NEUTRAL
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
Nov 18, 2025 • Zacks Commentary NEUTRAL
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Sentiment Snapshot

Average Sentiment Score:

0.249
50 articles with scored sentiment

Overall Sentiment:

Bullish

ADMA Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.14
  • Estimate: $0.15
  • Whisper: —
  • Surprise %: -6.7%
May 07, 2025
Mar 31, 2025 (Pre market)
-0.04 Surprise
  • Reported EPS: $0.11
  • Estimate: $0.15
  • Whisper: —
  • Surprise %: -25.0%
Mar 03, 2025
Dec 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.14
  • Estimate: $0.14
  • Whisper: —
  • Surprise %: -6.2%
Nov 07, 2024
Sep 30, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $0.15
  • Estimate: $0.13
  • Whisper: —
  • Surprise %: 15.4%
Aug 08, 2024
Jun 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.13
  • Estimate: $0.08
  • Whisper: —
  • Surprise %: 62.5%
May 09, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $0.08
  • Estimate: $0.06
  • Whisper: —
  • Surprise %: 33.3%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.11 Surprise
  • Reported EPS: $-0.08
  • Estimate: $0.03
  • Whisper: —
  • Surprise %: -366.7%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $0.01
  • Estimate: $-0.01
  • Whisper: —
  • Surprise %: 200.0%
Aug 09, 2023
Jun 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.03
  • Estimate: $-0.02
  • Whisper: —
  • Surprise %: -50.0%

Financials